1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)

L. Paz-Ares; M.A. Socinski; J. Shahidi; R.R. Hozak; V. Soldatenkova; N. Thatcher; F. Hirsch

doi:10.1016/s1556-0864(16)30326-4

1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)

Journal of Thoracic Oncology ◽

10.1016/s1556-0864(16)30326-4 ◽

2016 ◽

Vol 11 (4) ◽

pp. S153 ◽

Cited By ~ 3

Author(s):

L. Paz-Ares ◽

M.A. Socinski ◽

J. Shahidi ◽

R.R. Hozak ◽

V. Soldatenkova ◽

...

Keyword(s):

Growth Factor Receptor ◽

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study ◽

Epidermal Growth

Download Full-text

SQUIRE: a randomised, multicentre, open-label, phase III study of gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC); Subgroup efficacy and safety data for pts with epidermal growth factor receptor (EGFR)-expressing tumours

Annals of Oncology ◽

10.1093/annonc/mdw332.05 ◽

2016 ◽

Vol 27 ◽

pp. iv4

Author(s):

N. Zilembo ◽

L. Giannetta ◽

L. Crinò ◽

A. Bearz ◽

D. Amoroso ◽

...

Keyword(s):

Safety Data ◽

Growth Factor Receptor ◽

Stage Iv ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study ◽

Epidermal Growth

Download Full-text

Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer

Annals of Oncology ◽

10.1093/annonc/mdw214 ◽

2016 ◽

Vol 27 (8) ◽

pp. 1573-1579 ◽

Cited By ~ 41

Author(s):

L. Paz-Ares ◽

M.A. Socinski ◽

J. Shahidi ◽

R.R. Hozak ◽

V. Soldatenkova ◽

...

Keyword(s):

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Egfr Expression ◽

Open Label Phase ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

Squire: a Randomized, Multicenter, Open-Label, Phase III Study of Gemcitabine-Cisplatin (Gc) Chemotherapy Plus Necitumumab (Imc-11F8/Ly3012211) Vs Gc Alone in the First-Line Treatment of Patients (Pts) with Stage Iv Squamous Non-Small Cell Lung Cancer (Sq-Nsclc): Update on Key Subgroups

Annals of Oncology ◽

10.1093/annonc/mdu349.11 ◽

2014 ◽

Vol 25 ◽

pp. iv430 ◽

Cited By ~ 1

Author(s):

M.A. Socinski ◽

L. Paz-Ares ◽

A.V. Luft ◽

A. Szczesna ◽

T.E. Ciuleanu ◽

...

Keyword(s):

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.8008 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 8008-8008 ◽

Cited By ~ 18

Author(s):

Nick Thatcher ◽

Fred R. Hirsch ◽

Aleksandra Szczesna ◽

Tudor-Eliade Ciuleanu ◽

Wojciech Szafranski ◽

...

Keyword(s):

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

Subgroup Analysis of Elderly Patients in Squire: a Randomized, Multicenter, Open-Label, Phase Iii Study of Necitumumab (N) Plus Gemcitabine-Cisplatin (GC) Chemotherapy Versus Gc Alone in First-Line Treatment of Patients (PTS) with Stage Iv Squamous Non-Small Cell Lung Cancer (SQ-NSCLC)

Annals of Oncology ◽

10.1093/annonc/mdv050.07 ◽

2015 ◽

Vol 26 ◽

pp. i29 ◽

Cited By ~ 2

Author(s):

N. Thatcher ◽

T.-E. Ciuleanu ◽

R. Ramlau ◽

C. Schumann ◽

L. Paz-Ares ◽

...

Keyword(s):

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1097/jto.0000000000000366 ◽

2015 ◽

Vol 10 (1) ◽

pp. 134-142 ◽

Cited By ~ 75

Author(s):

Ralph G. Zinner ◽

Coleman K. Obasaju ◽

David R. Spigel ◽

Robert W. Weaver ◽

J. Thaddeus Beck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study

Download Full-text

Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.8004 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 8004-8004 ◽

Cited By ~ 21

Author(s):

James Chih-Hsin Yang ◽

Lecia V. Sequist ◽

Martin H. Schuler ◽

Tony Mok ◽

Nobuyuki Yamamoto ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor Receptor ◽

Pooled Analysis ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Open Label ◽

Open Label Phase ◽

Epidermal Growth ◽

Phase Iii Studies

Download Full-text

Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1097/jto.0000000000000517 ◽

2015 ◽

Vol 10 (6) ◽

pp. 883-889 ◽

Cited By ~ 37

Author(s):

Sarayut L Geater ◽

Chong-Rui Xu ◽

Caicun Zhou ◽

Cheng-Ping Hu ◽

Jifeng Feng ◽

...

Keyword(s):

Egfr Mutation ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Open Label ◽

Asian Patients ◽

Open Label Phase ◽

Phase Iii Study ◽

Life Improvement

Download Full-text

30MO ORIENT-3: A randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC)

Annals of Oncology ◽

10.1016/j.annonc.2020.10.517 ◽

2020 ◽

Vol 31 ◽

pp. S1428

Author(s):

Y. Shi ◽

L. Wu ◽

X. Yu ◽

P. Xing ◽

J. Zhou ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study ◽

Previously Treated

Download Full-text

Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2020.11.026 ◽

2020 ◽

Author(s):

Ligang Xing ◽

Gang Wu ◽

Luhua Wang ◽

Jiancheng Li ◽

Jianhua Wang ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor Receptor ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

Open Label ◽

Phase 2 Trial ◽

Unresectable Stage ◽

Open Label Phase ◽

Epidermal Growth

Download Full-text